Cargando…

Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study

BACKGROUND: Generalized pustular psoriasis (GPP), which can occur with or without psoriasis vulgaris (PV), is a severe form of pustular psoriasis with potentially life-threatening symptoms. GPP is also associated with several comorbidities, which further adds to the burden of disease. This study inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Löfvendahl, Sofia, Norlin, Jenny M, Schmitt-Egenolf, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084503/
https://www.ncbi.nlm.nih.gov/pubmed/35548662
http://dx.doi.org/10.2147/PTT.S359011
_version_ 1784703625123069952
author Löfvendahl, Sofia
Norlin, Jenny M
Schmitt-Egenolf, Marcus
author_facet Löfvendahl, Sofia
Norlin, Jenny M
Schmitt-Egenolf, Marcus
author_sort Löfvendahl, Sofia
collection PubMed
description BACKGROUND: Generalized pustular psoriasis (GPP), which can occur with or without psoriasis vulgaris (PV), is a severe form of pustular psoriasis with potentially life-threatening symptoms. GPP is also associated with several comorbidities, which further adds to the burden of disease. This study investigates the economic burden of disease in patients with GPP. METHODS: All-cause and GPP-specific healthcare resource use (inpatient stays, physician visits and drug use), as well as associated costs, were compared for year 2015 between GPP patients (n = 914) and two matched control groups representing the general population (n = 4047) and patients with PV but no GPP (n = 2556). Information on resource use for 2015 was obtained from the Swedish National Patient Register and Swedish Prescribed Drug Register, respectively. RESULTS: All-cause inpatient stays, physician visits, and use of psoriasis-related drugs were significantly more common among GPP patients compared to both control groups. This difference was reflected in total direct cost for GPP patients (5062 euros/year) which was 3.1 and 1.8 times higher (p < 0.001) compared to the general population and PV controls, respectively. For GPP patients, the share of total cost was 22% for all-cause physician outpatient visits and 40% for all-cause inpatient stays. However, only 6.3% and 11.3% of these costs, respectively, were due to GPP-specific problems. Psoriasis-related drugs constituted 27% of total costs for GPP patients of which a large fraction (86%) was represented by biologics. CONCLUSION: This study demonstrates a higher economic burden for GPP patients compared to both the general population and patients with PV, with inpatient visits and use of biologic drugs as major cost driving factors. Only fractions of the costs for physician visits and inpatient stays were attributable to specific GPP problems, indicating a higher economic burden of GPP-consequences and complications.
format Online
Article
Text
id pubmed-9084503
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90845032022-05-10 Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study Löfvendahl, Sofia Norlin, Jenny M Schmitt-Egenolf, Marcus Psoriasis (Auckl) Original Research BACKGROUND: Generalized pustular psoriasis (GPP), which can occur with or without psoriasis vulgaris (PV), is a severe form of pustular psoriasis with potentially life-threatening symptoms. GPP is also associated with several comorbidities, which further adds to the burden of disease. This study investigates the economic burden of disease in patients with GPP. METHODS: All-cause and GPP-specific healthcare resource use (inpatient stays, physician visits and drug use), as well as associated costs, were compared for year 2015 between GPP patients (n = 914) and two matched control groups representing the general population (n = 4047) and patients with PV but no GPP (n = 2556). Information on resource use for 2015 was obtained from the Swedish National Patient Register and Swedish Prescribed Drug Register, respectively. RESULTS: All-cause inpatient stays, physician visits, and use of psoriasis-related drugs were significantly more common among GPP patients compared to both control groups. This difference was reflected in total direct cost for GPP patients (5062 euros/year) which was 3.1 and 1.8 times higher (p < 0.001) compared to the general population and PV controls, respectively. For GPP patients, the share of total cost was 22% for all-cause physician outpatient visits and 40% for all-cause inpatient stays. However, only 6.3% and 11.3% of these costs, respectively, were due to GPP-specific problems. Psoriasis-related drugs constituted 27% of total costs for GPP patients of which a large fraction (86%) was represented by biologics. CONCLUSION: This study demonstrates a higher economic burden for GPP patients compared to both the general population and patients with PV, with inpatient visits and use of biologic drugs as major cost driving factors. Only fractions of the costs for physician visits and inpatient stays were attributable to specific GPP problems, indicating a higher economic burden of GPP-consequences and complications. Dove 2022-05-05 /pmc/articles/PMC9084503/ /pubmed/35548662 http://dx.doi.org/10.2147/PTT.S359011 Text en © 2022 Löfvendahl et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Löfvendahl, Sofia
Norlin, Jenny M
Schmitt-Egenolf, Marcus
Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
title Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
title_full Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
title_fullStr Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
title_full_unstemmed Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
title_short Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
title_sort economic burden of generalized pustular psoriasis in sweden: a population-based register study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084503/
https://www.ncbi.nlm.nih.gov/pubmed/35548662
http://dx.doi.org/10.2147/PTT.S359011
work_keys_str_mv AT lofvendahlsofia economicburdenofgeneralizedpustularpsoriasisinswedenapopulationbasedregisterstudy
AT norlinjennym economicburdenofgeneralizedpustularpsoriasisinswedenapopulationbasedregisterstudy
AT schmittegenolfmarcus economicburdenofgeneralizedpustularpsoriasisinswedenapopulationbasedregisterstudy